Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Oxonica Completes £2.6 million Rights Issue

Abstract:
The Group has raised approximately £2.6 million through the issue of 38,478 new ordinary shares £67.89 per share.

Oxonica Completes £2.6 million Rights Issue and Employee Subscription

February 7, 2005

Oxonica Limited, a leading European group developing commercial solutions based on nanotechnology, announces today that it has completed a further round of financing, through a Rights Issue and Employee Subscription.

The Group has raised approximately £2.6 million through the issue of 38,478 new ordinary shares £67.89 per share. This includes 2,006 shares issued to employees who were invited to subscribe for shares at the Rights Issue price. The issue was substantially underwritten by Seighford Investment Company Limited and Mr Richard Farleigh, both of whom were founder investors in Oxonica and was well supported by the Group’s shareholders, including the three largest investors; BASF Venture Capital GmbH, Foresight Technology VCT and TriVest VCT.

As well as raising additional funds, the Rights Issue triggered a previously agreed restructuring of the Group’s share capital as a result of which Oxonica now has a single class of ordinary shares.

The greater part of the proceeds will be used to provide working capital and to support the global commercial roll-out of the Group’s market leading products; Envirox (Tm) Fuel Borne Catalyst and Optisol (TM) UV Absorber. Envirox has already been adopted by Stagecoach Group plc for use in its UK bus fleet and an agreement has also been signed with DMX Technology Corp to distribute the product into premium branded diesel fuel in the Philippines, in partnership with BASF. Optisol has been selected by Boots Group as the UV filter for incorporation into their new range of Soltan Facial Suncare products.

Commenting on the Rights Issue, Dr Kevin Matthews, Oxonica’s Chief Executive said:
“We are delighted with the response to the Rights Issue, particularly as it demonstrates a high degree of confidence on the part of both shareholders and employees in Oxonica as it begins the full-scale, global commercialisation of a number of key technologies.”

Richard Clarke, Oxonica’s CFO added:
“Following the Rights Issue and associated restructuring, Oxonica now has a straightforward capital structure, which will facilitate future corporate development. Most importantly, it has successfully raised funds to take the company to the next stage of growth.”



Contact:
Sonia Bouzid
Oxonica
sonia.bouzid@oxonica.com
+44 1865 856700

Nigel Robson
Vortex PR
Island House, Forest Road, Guernsey, GY8 0AB, UK
+44 (0) 1481 233080
Fax +44 (0) 1481 233082
nigel@vortexpr.com

Copyright © Oxonica

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017

Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017

Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017

Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016

Announcements

Tiny nanoclusters could solve big problems for lithium-ion batteries February 21st, 2017

Strem Chemicals and Dotz Nano Ltd. Sign Distribution Agreement for Graphene Quantum Dots Collaboration February 21st, 2017

Oxford Instruments announces Dr Brad Ramshaw of Cornell University, as winner of the 2017 Lee Osheroff Richardson Science Prize February 20th, 2017

Breakthrough with a chain of gold atoms: In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport February 20th, 2017

Financial Reports

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results January 31st, 2017

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 7, 2017 January 19th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project